SCHEMBL19249205

SCHEMBL19249205

CC(C)(C)OC(=O)NCc1cc(OC(=O)OC(C)(C)C)c2cc(-n3cccn3)ccc2n1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CA1 P00915 2/20 0.38
▸ CA2 P00918 2/20 0.38
▸ CA9 Q16790 2/20 0.38
▸ CA4 P22748 1/20 0.38
▸ CA7 P43166 1/20 0.38
▸ CA12 O43570 1/20 0.38
▸ SYK P43405 1/20 0.37
▸ BTK Q06187 2/20 0.36
▸ LMNA P02545 1/20 0.35
▸ KDM4A O75164 1/20 0.35
▸ GPR119 Q8TDV5 1/20 0.35
▸ RORC P51449 1/20 0.34
▸ NLRP3 Q96P20 2/20 0.34
▸ PCSK9 Q8NBP7 1/20 0.34
▸ NAMPT P43490 3/20 0.34
▸ BMX P51813 1/20 0.34
▸ PIK3CD O00329 1/20 0.34
▸ PIK3CA P42336 1/20 0.34
▸ PIK3CB P42338 1/20 0.34
▸ PIK3CG P48736 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20721075 0.94 BTK (0.37) SYKBTKLMNAGPR119RORC
SCHEMBL23507767 0.80 EGFR (0.39) KDM4A
SCHEMBL19249157 0.78 KDM4A (0.39) KDM4A
SCHEMBL4404243 0.73 LMNA (0.54) LMNANAMPT
SCHEMBL19211202 0.73 ALDH1A1 (0.40) —
SCHEMBL23491567 0.73 HDAC1 (0.41) CA2SYKKDM4A
SCHEMBL19249244 0.72 CA2 (0.40) CA1CA2CA9CA12
SCHEMBL19211218 0.71 MEN1 (0.37) CA2
SCHEMBL19248873 0.69 NQO2 (0.45) SYKKDM4A
SCHEMBL20729327 0.68 CYP2C9 (0.37) CA1CA2CA9CA12LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3414229-B1 QUINOLINONE LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF PHARMAKEA INC (US) 2021-06-16 — — EP disclosed
US-10588900-B2 Quinolinone lysyl oxidase-like 2 inhibitors and uses thereof PHARMAKEA, INC. (US) 2020-03-17 — — US disclosed
US-20190046520-A1 QUINOLINONE LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF PHARMAKEA, INC. 2019-02-14 — — US disclosed
WO-2017139274-A1 QUINOLINONE LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF PHARMAKEA, INC. (US) 2017-08-17 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190046520-A1 QUINOLINONE LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF LOXL2, LOXL1, LOX CA1 4209/4885CA2 1552/4885CA9 3212/4885
US-10588900-B2 Quinolinone lysyl oxidase-like 2 inhibitors and uses thereof LOXL2, LOXL1, LOX CA1 4209/4885CA2 1552/4885CA9 3212/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback